Story perspectives

Moderna Settles $2.25B Patent Dispute, Stock Surges 10%

3/4/2026

Summary

Story summary

Moderna settled a patent dispute with Genevant Sciences and Arbutus Biopharma for up to $2.25 billion over lipid nanoparticle (LNP) technology used in its COVID-19 vaccine.
The settlement includes a $950 million upfront payment due in July 2026 and $1.3 billion contingent on a separate legal appeal.
The agreement eliminates future royalty obligations for Moderna's upcoming vaccines, reducing financial uncertainty.
Moderna's stock rose over 10% after the announcement.

1 of 1

Story summary

Moderna settled a patent dispute with Genevant Sciences and Arbutus Biopharma for up to $2.25 billion over lipid nanoparticle (LNP) technology used in its COVID-19 vaccine.
The settlement includes a $950 million upfront payment due in July 2026 and $1.3 billion contingent on a separate legal appeal.
The agreement eliminates future royalty obligations for Moderna's upcoming vaccines, reducing financial uncertainty.
Moderna's stock rose over 10% after the announcement.